Mr. Roy recently penned a report detailing market-based solutions for making new medicines more affordable.
One of his solutions involves encouraging drugmakers to produce more “me too” drugs to achieve price competition and drive down prices.
“‘[M]e-too’ drugs, which are chemically or mechanistically similar to existing drugs, are often derided because they are less innovative than drugs that create entirely new categories or address an unmet medical need,” wrote Mr. Roy. “But [they] can help insurers and pharmacy benefit managers reduce costs for consumers.”
To view the full report, click here.
More articles on supply chain:
6 ways PBMs influence the drug market
FDA safety warning: Diabetes drug causes higher risk of foot, leg amputations
Pharma websites prioritize ads over education, physicians say
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
